(S)-4-(7-allyl-9-cyclopentyl-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide | 1157848-34-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 嘧啶二氮卓类
• 英文名称: (S)-4-(7-allyl-9-cyclopentyl-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide
• 英文别名: 4-[[(7S)-9-cyclopentyl-5-methyl-6-oxo-7-prop-2-enyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide
• CAS: 1157848-34-4
• 化学式: C₃₀H₄₁N₇O₃
• 分子量: 547.701
• InChiKey: DWBXNQKRJAOIHK-NRFANRHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  40
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-chloro-9-cyclopentyl-5-methyl-5,7,8,9-tetrahydro-6H-pyrimido[4,5-b][1,4]diazepin-6-one 在 盐酸 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 异丙醇 为溶剂， 生成 (S)-4-(7-allyl-9-cyclopentyl-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide
  参考文献：
  名称：

  Discovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1)

  摘要：

  Using structure-based drug design, we identified and optimized a novel series of pyrimidodiazepinone PLK1 inhibitors resulting in the selection of the development candidate TAK-960. TAK-960 is currently undergoing Phase I evaluation in adult patients with advanced solid malignancies. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.083

文献信息

• [EN] POLO-LIKE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE DE TYPE POLO
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2009067547A1

  公开（公告）日：2009-05-28

  Compounds of the following formula are provided for use with kinases, wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  提供以下公式的化合物供激酶使用，其中变量如本文所定义。还提供包含这些化合物的药物组合物、试剂盒和制造物品；用于制备这些化合物的方法和中间体；以及使用这些化合物的方法。
• POLO-LIKE KINASE INHIBITORS
  申请人：Cao Sheldon X.

  公开号：US20090291938A1

  公开（公告）日：2009-11-26

  Compounds of the following formula are provided for use with kinases: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  提供了以下公式的化合物，用于与激酶一起使用：其中变量的定义如下。还提供了包含这些化合物的制药组合物、工具包和制造物品；用于制造这些化合物的方法和中间体；以及使用这些化合物的方法。
• Discovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1)
  作者：Zhe Nie、Victoria Feher、Srinivasa Natala、Christopher McBride、Andre Kiryanov、Benjamin Jones、Betty Lam、Yan Liu、Stephen Kaldor、Jeffrey Stafford、Kouki Hikami、Noriko Uchiyama、Tomohiro Kawamoto、Yuichi Hikichi、Shin-ichi Matsumoto、Nobuyuki Amano、Lilly Zhang、David Hosfield、Robert Skene、Hua Zou、Xiaodong Cao、Takashi Ichikawa

  DOI：10.1016/j.bmcl.2013.02.083

  日期：2013.6

  Using structure-based drug design, we identified and optimized a novel series of pyrimidodiazepinone PLK1 inhibitors resulting in the selection of the development candidate TAK-960. TAK-960 is currently undergoing Phase I evaluation in adult patients with advanced solid malignancies. (C) 2013 Elsevier Ltd. All rights reserved.